PRKRA/PACT Rabbit Monoclonal Antibody for WB, IHC-P, ELISA - O75569

Core Product Specifications and Parameters

Biological Background: PRKRA/PACT Function and Localization

• PRKRA, also known as PACT (PKR activator), is an interferon-inducible double-stranded RNA-dependent protein kinase activator encoded by the PRKRA gene.
• It activates EIF2AK2/PKR in the absence of dsRNA, leading to phosphorylation of eIF2α and subsequent inhibition of translation and induction of apoptosis.
• PRKRA is required for siRNA production by DICER1 and for siRNA-mediated post-transcriptional gene silencing, but not for pre-miRNA processing.
• It promotes UBC9-p53/TP53 association, leading to sumoylation and phosphorylation of p53, enhancing its transcriptional activity in a PKR-dependent manner.
• The protein localizes to the cytoplasm, particularly the perinuclear region.
• Keywords associated with PRKRA include alternative splicing, phosphoprotein, RNA-binding, and host-virus interaction, and mutations are linked to dystonia and parkinsonism (DYT16).
• The UniProt-annotated molecular weight is ~34.4 kDa.

Experimental Guidance and Technical Tips

• The immunogen corresponds to a peptide within amino acids 214–313 of human PRKRA/PACT, which may confer target specificity; consider sequence alignment to assess cross-reactivity in your species of interest.
• For Western blot, the predicted molecular weight is approximately 34 kDa; validate the observed band in your sample lysate, and optimize loading amounts and antibody dilution accordingly.
• In immunohistochemistry (IHC-P), antigen retrieval conditions and antibody titration should be empirically determined for your tissue type and fixation protocol.
• For ELISA, the antibody can be explored as a capture or detection reagent in sandwich immunoassays; pairing with another PRKRA-specific antibody may be tested.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio provides diagnostic manufacturers, laboratories, and research institutes with streamlined access to high-quality IVD raw materials, including validated monoclonal antibodies against targets like PRKRA/PACT for studying PKR signaling, RNA silencing, and apoptosis. Our integrated platform supports bulk procurement of optimized antibodies, recombinant proteins, and ancillary reagents, alongside custom sourcing for rare and emerging targets. Whether advancing cancer diagnostics or virology assays, CamelBio accelerates your development pipeline from concept to clinic.